CollPlant Biotechnologies Ltd CLGN
Regular-session close
After hours · Nov 12, 4:00 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 14.27M
- Revenue (ttm)
- 689.00K
- EPS (ttm)
- -9.33
- Shares out
- 11.45M
- Forward P/E
- -8.82
- YTD return
- 0.00%
- 1-year return
- 0.00%
- 50-day average
- 4.04
- Volume
- 125.27K
- Avg volume
- 384.96K
- Open
- 4.05
- Previous close
- 3.96
- Day's range
- 4.05 – 4.64
- 52-week range
- 2.64 – 22.50
- Beta
- 0.48
- Price target
- 12.50 (+169.4%)
Key statistics
- 200-day average
- 4.90
- Enterprise value
- 33.32M
- Price / sales
- 57.19
- Price / book
- 1.39
- Revenue growth
- -97.60%
- Free cash flow
- 2.13M
- Total cash
- 18.92M
- Total debt
- 3.38M
- Return on equity
- -61.55%
- Short % of float
- 0.15%
Fundamental scorecard
4 of 25 checks passed on CLGN’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 27, 2024 | Sep 1, 2024 | -0.37 | -0.38 | -0.01 | -2.70% |
| Aug 20, 2024 | Jun 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| Aug 20, 2024 | Jun 1, 2024 | -0.35 | — | — | — |
| May 29, 2024 | Mar 1, 2024 | -0.35 | -0.37 | -0.02 | -5.71% |
| May 29, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -0.42 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 27, 2024 | D. Boral Capital | main | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 20, 2024 | EF Hutton | main | Buy | Buy |
| Aug 5, 2024 | EF Hutton | init | — | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- collplant.com
News
CollPlant Says Israel Innovation Authority Approves Grant Of ~$1.8M To Its Subsidiary, LightSolver, To Support Continued Development Of LPU, All-Optical, Laser-Based Computing Platform
Reported Earlier: CollPlant Subsidiary LightSolver Signs Multi-Year Israel Defense Ministry Agreement For Photonic Computing, Secures Initial 12-Month Order In Defense Market With Estimated $5B Annual TAM, 15% CAGR
Your note
Sign in to keep a note on CLGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Villere St. Denis J. & Co. LLC | 4.33% | 484,867 | 1.67M | Sep 29, 2024 |
| Pinnacle Associates, Ltd. | 4.18% | 468,109 | 1.61M | Sep 29, 2024 |
| Brown Advisory Inc. | 1.07% | 119,465 | 410.96K | Sep 29, 2024 |
| AMH Equity Ltd. | 0.89% | 99,205 | 341.26K | Sep 29, 2024 |
| Benjamin Edwards, Inc. | 0.21% | 23,810 | 81.91K | Sep 29, 2024 |
| Pathstone Holdings, LLC | 0.15% | 17,000 | 58.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 5,925 | 20.38K | Oct 30, 2024 |
